Avasare Rupali S, Andeen Nicole K, Havasi Andrea, Hogan Jonathan J
Division of Nephrology, Department of Medicine, Oregon Health & Science University, Portland, OR 97239, USA.
Department of Pathology, Oregon Health & Science University, Portland, OR 97239, USA.
J Clin Med. 2021 Apr 12;10(8):1633. doi: 10.3390/jcm10081633.
Dysproteinemic kidney diseases are disorders that occur as the result of lymphoproliferative (B cell or plasma cell) disorders that cause kidney damage via production of nephrotoxic monoclonal immunoglobulins or their components. These monoclonal immunoglobulins have individual physiochemical characteristics that confer specific nephrotoxic properties. There has been increased recognition and revised characterization of these disorders in the last decade, and in some cases, there have been substantial advances in disease understanding and treatments, which has translated to improved patient outcomes. These disorders still present challenges to nephrologists and patients, since they are rare, and the field of hematology is rapidly changing with the introduction of novel testing and treatment strategies. In this review, we will discuss the clinical presentation, kidney biopsy features, hematologic characteristics and treatment of dysproteinemic kidney diseases.
异常蛋白血症性肾脏疾病是由于淋巴增殖性疾病（B细胞或浆细胞疾病）导致肾损害的疾病，这些疾病通过产生肾毒性单克隆免疫球蛋白或其成分而引起肾脏损伤。这些单克隆免疫球蛋白具有赋予特定肾毒性特性的个体理化特征。在过去十年中，对这些疾病的认识有所增加，其特征也得到了修订，在某些情况下，在疾病理解和治疗方面取得了重大进展，这已转化为患者预后的改善。这些疾病仍然给肾病学家和患者带来挑战，因为它们很罕见，而且随着新型检测和治疗策略的引入，血液学领域正在迅速变化。在本综述中，我们将讨论异常蛋白血症性肾脏疾病的临床表现、肾活检特征、血液学特征和治疗方法。
